- Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Cancers. 2016 Academic Article GET IT
Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Times cited: 2
- A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. The Journal of urology. 2014 Academic Article GET IT
- PSMA-targeted dendrimers: a patent evaluation (WO2012078534). Expert opinion on therapeutic patents. 2013 Academic Article GET IT